Press Releases
Rapid Generation of Targeted Antibacterial Agents in Response to Serious Food Safety Pathogens Detailed by AvidBiotics in PLoS ONE
Highly Specific Purocin™ Protein Quickly Generated Against German E. coli O104 Using Draft Genomic Sequence via AvidBiotics’ Antibacterial Protein Platform Continue»
DGR Technology Platform for Engineering Proteins Advanced in Publication by AvidBiotics Collaborators
South San Francisco, CA (December 15, 2011): AvidBiotics today announced the publication of new findings in PLoS Genetics that could enable genetic Continue»
AvidBiotics’ Targeted Antibacterial Proteins Show Potential to Address Food-Borne Bacterial Infections, Provide Antibiotic Alternative
New Publication Demonstrates Ability of Avidocin™ Proteins to Prevent and Treat E. coli O157 Diarrhea in Animal Study Continue»
Two New Grants for Targeted Antibacterial Proteins
South San Francisco, CA: AvidBiotics today announced the receipt of two new grants totaling $1 million dollars Continue»
Articles
Genome Sequence of E. coli O104:H4 Leads to Rapid Development of a Targeted Antimicrobial Agent against This Emerging Pathogen
By: Dean Scholl, Dana Gebhart, Steven R. Williams, Anna Bates, Robert Mandrell |
Source: plosone.org
A recent widespread outbreak of Escherichia coli O104:H4 in Germany demonstrates the dynamic nature of emerging and re-emerging food-borne pathogens, particularly STECs and related pathogenic E. coli. Continue»
One-on-One with Jim Knighton of AvidBiotics
By: Ron Leuty |
Source: San Francisco Business Times
AvidBiotics Corp. started work in human therapeutics several years ago, but it’s really taken a liking to food. Continue»
AvidBiotics: Punching Holes In Bacterial Resistance
By: Suzanne Elvidge |
Source: Life Science Leader
Bacterial infection is a huge and growing medical burden worldwide — the Centers for Disease Control and Prevention estimates Continue»
AvidBiotics Creates Novel Proteins that Kill Bacteria on the Farm, in the Lab, in the Body
By: Luke Timmerman |
Source: XConomy.com
Dave Martin is one of the people in biotech who has truly seen it all. In the ’80s, the industry’s early days, he was head of R&D at Genentech. Continue»